{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:05:56Z","timestamp":1767830756309,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"stichting RUN","award":["R 0003057"],"award-info":[{"award-number":["R 0003057"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.autrev.2020.102515","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T04:22:00Z","timestamp":1583986920000},"page":"102515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels"],"prefix":"10.1016","volume":"19","author":[{"given":"Ruben L.","family":"Smeets","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigit E.","family":"Kersten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma","family":"Joosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Kaffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wynand","family":"Alkema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J.P.M.","family":"Koenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madelon C.","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.autrev.2020.102515_bb0005","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102515_bb0010","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/art.11113","article-title":"Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies","volume":"49","author":"Reveille","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2020.102515_bb0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12016-012-8331-1","article-title":"Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma","volume":"43","author":"Moinzadeh","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102515_bb0020","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00281-015-0506-4","article-title":"Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment","volume":"37","author":"Affandi","year":"2015","journal-title":"Semin Immunopathol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102515_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2007.12.001","article-title":"The many faces of scleroderma","volume":"34","author":"Steen","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"issue":"11","key":"10.1016\/j.autrev.2020.102515_bb0030","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.autrev.2020.102515_bb0035","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.socscimed.2012.07.031","article-title":"Personalizing medicine: futures present and past","volume":"75","author":"Tutton","year":"2012","journal-title":"Soc Sci Med"},{"issue":"6","key":"10.1016\/j.autrev.2020.102515_bb0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11926-014-0425-8","article-title":"Personalized medicine in systemic sclerosis: facts and promises","volume":"16","author":"Dobrota","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"8","key":"10.1016\/j.autrev.2020.102515_bb0045","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/art.24681","article-title":"Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials","volume":"60","author":"Amjadi","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.autrev.2020.102515_bb0050","first-page":"1281","article-title":"Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis","volume":"22","author":"Clements","year":"1995","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102515_bb0055","first-page":"84","article-title":"The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis","volume":"25","author":"Furst","year":"1998","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102515_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"issue":"7","key":"10.1016\/j.autrev.2020.102515_bb0065","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/art.22721","article-title":"Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model","volume":"56","author":"Shand","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2020.102515_bb0070","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology Provisional Composite Response Index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2020.102515_bb0075","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41584-018-0021-9","article-title":"Existing and novel biomarkers for precision medicine in systemic sclerosis","volume":"14","author":"Wermuth","year":"2018","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102515_bb0080","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2020.102515_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08916934.2017.1416467","article-title":"IL-17 and related cytokines involved in systemic sclerosis: perspectives","volume":"51","author":"Goncalves","year":"2018","journal-title":"Autoimmunity"},{"issue":"2","key":"10.1016\/j.autrev.2020.102515_bb0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/cei.13009","article-title":"Interleukin-9 over-expression and T helper 9 polarization in systemic sclerosis patients","volume":"190","author":"Guggino","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2020.102515_bb0095","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/08916934.2017.1357699","article-title":"Disease-related autoantibody profile in patients with systemic sclerosis","volume":"50","author":"Liaskos","year":"2017","journal-title":"Autoimmunity"},{"issue":"11","key":"10.1016\/j.autrev.2020.102515_bb0100","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2020.102515_bb0105","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.autrev.2020.102515_bb0110","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/art.1780390712","article-title":"Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis","volume":"39","author":"Arnett","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.autrev.2020.102515_bb0115","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3899\/jrheum.160574","article-title":"Antifibrillarin antibodies are associated with native north American ethnicity and poorer survival in systemic sclerosis","volume":"44","author":"Mejia Otero","year":"2017","journal-title":"J Rheumatol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102515_bb0120","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3899\/jrheum.100316","article-title":"Anti-Th\/to are common antinucleolar autoantibodies in Italian patients with scleroderma","volume":"37","author":"Ceribelli","year":"2010","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102515_bb0125","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.autrev.2014.11.007","article-title":"Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th\/to autoantigen","volume":"14","author":"Mahler","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2020.102515_bb0130","first-page":"67","article-title":"Clinical relevance and HLA association of autoantibodies against the nucleolus organizer region (NOR-90)","volume":"22","author":"Dick","year":"1995","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2020.102515_bb0135","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/art.39316","article-title":"Interpretation of an extended autoantibody profile in a well-characterized Australian systemic sclerosis (scleroderma) cohort using principal components analysis","volume":"67","author":"Patterson","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.autrev.2020.102515_bb0140","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.autrev.2018.06.009","article-title":"Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma - a review","volume":"17","author":"Nunes","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2020.102515_bb0145","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.gpb.2016.02.004","article-title":"Topoisomerase I in human disease pathogenesis and treatments","volume":"14","author":"Li","year":"2016","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"6","key":"10.1016\/j.autrev.2020.102515_bb0150","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00296-016-3636-7","article-title":"Interstitial lung disease in systemic sclerosis: current and future treatment","volume":"37","author":"Giacomelli","year":"2017","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.autrev.2020.102515_bb0155","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102515_bb0160","series-title":"Textbook on Systemic Sclerosis","author":"Eular","year":"2019"},{"issue":"6","key":"10.1016\/j.autrev.2020.102515_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17060990","article-title":"DNA damage and pulmonary hypertension","volume":"17","author":"Ranchoux","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.autrev.2020.102515_bb0170","doi-asserted-by":"crossref","first-page":"700","DOI":"10.14740\/jocmr3505w","article-title":"Soluble Fms-like tyrosine Kinase-1 is a marker of endothelial dysfunction during sepsis","volume":"10","author":"Greco","year":"2018","journal-title":"J Clin Med Res"},{"issue":"1","key":"10.1016\/j.autrev.2020.102515_bb0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1086\/679704","article-title":"Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension","volume":"5","author":"Al-Husseini","year":"2015","journal-title":"Pulm Circ"},{"key":"10.1016\/j.autrev.2020.102515_bb0180","doi-asserted-by":"crossref","first-page":"14678","DOI":"10.1038\/ncomms14678","article-title":"Alpha-amino trimethylation of CENP-A by NRMT is required for full recruitment of the centromere","volume":"8","author":"Sathyan","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.autrev.2020.102515_bb0185","first-page":"98","article-title":"Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis","volume":"106","author":"Iniesta Arandia","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102515_bb0190","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear antibodies in systemic sclerosis: an update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102515_bb0195","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/annrheumdis-2018-214382","article-title":"Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib","volume":"78","author":"Ricard","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102515_bb0200","doi-asserted-by":"crossref","first-page":"543704","DOI":"10.1155\/2010\/543704","article-title":"Scleroderma renal crisis: a pathology perspective","volume":"2010","author":"Batal","year":"2010","journal-title":"Int J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102515_bb0205","first-page":"41","article-title":"Clinical features of systemic sclerosis patients with anti-RNA polymerase III antibody in a single centre in Spain","volume":"119","author":"Callejas-Moraga","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102515_bb0210","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3899\/jrheum.160817","article-title":"Malignancies in patients with anti-RNA polymerase III antibodies and systemic sclerosis: analysis of the EULAR scleroderma trials and research cohort and possible recommendations for screening","volume":"44","author":"Lazzaroni","year":"2017","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2020.102515_bb0215","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/annrheumdis-2012-202357","article-title":"Implication of IL-2\/IL-21 region in systemic sclerosis genetic susceptibility","volume":"72","author":"Diaz-Gallo","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"7648","key":"10.1016\/j.autrev.2020.102515_bb0220","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature21706","article-title":"The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors","volume":"544","author":"Lefrancais","year":"2017","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.autrev.2020.102515_bb0225","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMcibr1817501","article-title":"Preventing preeclampsia by silencing soluble Flt-1?","volume":"380","author":"Robertson","year":"2019","journal-title":"N Engl J Med"},{"issue":"6\u20137","key":"10.1016\/j.autrev.2020.102515_bb0230","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ejcb.2011.07.006","article-title":"Signaling by IL-31 and functional consequences","volume":"91","author":"Cornelissen","year":"2012","journal-title":"Eur J Cell Biol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:16:44Z","timestamp":1761599804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220300677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1568997220300677"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102515","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102515"}}